Diffuse Large B-Cell Lymphoma Learner Survey

Question Title

* 1. What is your profession?

Physician

Physician Assistant

Nurse Practitioner

Nurse

Other (please specify):

Question Title

* 2. What is your primary specialty?

Oncology / Hematology

Internal Medicine

Family Medicine

Other (please specify)

Question Title

* 3. How aware are you of current recommendations by the NCCN regarding gene-expression profiling (GEP) classifications for the diagnosis of non-Hodgkin’s Lymphoma?

Extremely aware

Very aware

Moderately aware

Slightly aware

Not aware at all

Question Title

* 4. How aware are you of imaging tools (ie, PET/CT scans) for staging diffuse large B-cell lymphoma (DLBCL)?

Extremely aware

Very aware

Moderately aware

Slightly aware

Not aware at all

Question Title

* 5. How frequently do you use imaging tools (ie, PET/CT scans) to stage DLBCL?

Always

Frequently

Sometimes

Never

Question Title

* 6. How aware are you of new molecular markers for classifying DLBCL patients into prognostic groups?

Extremely aware

Very aware

Moderately aware

Slightly aware

Not aware at all

Question Title

* 7. If you are aware of these new molecular markers for classifying DLBCL, how often to you employ them to stage DLBCL?

Always

Most of the time

Sometimes

Never

Question Title

* 8. Which molecular markers do you use in diagnosing DLBCL sub-types?

TP53

TP21

MHCII gene expression

IGH-BCL2

MYC

Question Title

* 9. What factors determine your selection of first-line therapy in patients with germinal center B-cell like (GCB) DLBCL, which generally has a poorer response to standard rituximab-CHOP (R-CHOP) at greater risk of relapse?

Increase the dose of R-CHOP

Longer duration R-CHOP regimen

Longer duration of R-CHOP with bone-marrow transplantation

Longer treatment regimen of R-CHOP and radiation

Other (please explain):

Question Title

* 10. What other factors influence your selection of first-line therapy for DLBCL? (list all that apply)

Patient age

Cancer stage

Elevated lactate dehydrogenase levels

ECOG performance status

Question Title

* 11. How aware are you of new investigational agents that may decrease the risk of DLBCL relapse (maintenance therapy)?

Extremely aware

Very aware

Moderately aware

Slightly aware

Not aware at all

Question Title

* 12. What is your ideal maintenance therapy for patients with activated B-cell like (ABC) DLBCL?

Question Title

* 13. What is your ideal maintenance therapy for patients GCB-DLBCL?

Question Title

* 14. What do you believe is missing from the cadre of first-line agents and treatment regimens for the patients who fail to respond or relapse after initial therapy?

	Extremely confident	Very confident	Moderately confident	Slightly confident	Not at all confident
Identifying World Health Organization DLBCL subtypes	Identifying World Health Organization DLBCL subtypes Extremely confident	Identifying World Health Organization DLBCL subtypes Very confident	Identifying World Health Organization DLBCL subtypes Moderately confident	Identifying World Health Organization DLBCL subtypes Slightly confident	Identifying World Health Organization DLBCL subtypes Not at all confident
Recognizing symptoms and clinical presentations of DLBCL	Recognizing symptoms and clinical presentations of DLBCL Extremely confident	Recognizing symptoms and clinical presentations of DLBCL Very confident	Recognizing symptoms and clinical presentations of DLBCL Moderately confident	Recognizing symptoms and clinical presentations of DLBCL Slightly confident	Recognizing symptoms and clinical presentations of DLBCL Not at all confident
Coordinating with other clinicians in the development of treatment plans for patients with DLBCL	Coordinating with other clinicians in the development of treatment plans for patients with DLBCL Extremely confident	Coordinating with other clinicians in the development of treatment plans for patients with DLBCL Very confident	Coordinating with other clinicians in the development of treatment plans for patients with DLBCL Moderately confident	Coordinating with other clinicians in the development of treatment plans for patients with DLBCL Slightly confident	Coordinating with other clinicians in the development of treatment plans for patients with DLBCL Not at all confident
Counseling patients with DLBCL on treatment plans	Counseling patients with DLBCL on treatment plans Extremely confident	Counseling patients with DLBCL on treatment plans Very confident	Counseling patients with DLBCL on treatment plans Moderately confident	Counseling patients with DLBCL on treatment plans Slightly confident	Counseling patients with DLBCL on treatment plans Not at all confident

Extremely confident

Very confident

Moderately confident

Slightly confident

Not at all confident

Identifying World Health Organization DLBCL subtypes

Identifying World Health Organization DLBCL subtypes Extremely confident

Identifying World Health Organization DLBCL subtypes Very confident

Identifying World Health Organization DLBCL subtypes Moderately confident

Identifying World Health Organization DLBCL subtypes Slightly confident

Identifying World Health Organization DLBCL subtypes Not at all confident

Recognizing symptoms and clinical presentations of DLBCL

Recognizing symptoms and clinical presentations of DLBCL Extremely confident

Recognizing symptoms and clinical presentations of DLBCL Very confident

Recognizing symptoms and clinical presentations of DLBCL Moderately confident

Recognizing symptoms and clinical presentations of DLBCL Slightly confident

Recognizing symptoms and clinical presentations of DLBCL Not at all confident

Coordinating with other clinicians in the development of treatment plans for patients with DLBCL

Coordinating with other clinicians in the development of treatment plans for patients with DLBCL Extremely confident

Coordinating with other clinicians in the development of treatment plans for patients with DLBCL Very confident

Coordinating with other clinicians in the development of treatment plans for patients with DLBCL Moderately confident

Coordinating with other clinicians in the development of treatment plans for patients with DLBCL Slightly confident

Coordinating with other clinicians in the development of treatment plans for patients with DLBCL Not at all confident

Counseling patients with DLBCL on treatment plans

Counseling patients with DLBCL on treatment plans Extremely confident

Counseling patients with DLBCL on treatment plans Very confident

Counseling patients with DLBCL on treatment plans Moderately confident

Counseling patients with DLBCL on treatment plans Slightly confident

Counseling patients with DLBCL on treatment plans Not at all confident

	Extremely confident	Very confident	Moderately confident	Slightly confident	Not at all confident
Selection of first-line therapy for GCB-DLBCL	Selection of first-line therapy for GCB-DLBCL Extremely confident	Selection of first-line therapy for GCB-DLBCL Very confident	Selection of first-line therapy for GCB-DLBCL Moderately confident	Selection of first-line therapy for GCB-DLBCL Slightly confident	Selection of first-line therapy for GCB-DLBCL Not at all confident
Selection of first-line therapy for ABC-DLBCL	Selection of first-line therapy for ABC-DLBCL Extremely confident	Selection of first-line therapy for ABC-DLBCL Very confident	Selection of first-line therapy for ABC-DLBCL Moderately confident	Selection of first-line therapy for ABC-DLBCL Slightly confident	Selection of first-line therapy for ABC-DLBCL Not at all confident
Selection of first-line therapy for primary mediastinal large B-cell lymphoma	Selection of first-line therapy for primary mediastinal large B-cell lymphoma Extremely confident	Selection of first-line therapy for primary mediastinal large B-cell lymphoma Very confident	Selection of first-line therapy for primary mediastinal large B-cell lymphoma Moderately confident	Selection of first-line therapy for primary mediastinal large B-cell lymphoma Slightly confident	Selection of first-line therapy for primary mediastinal large B-cell lymphoma Not at all confident
Newer second-line treatment regimens for use as salvage therapy for DLBCL	Newer second-line treatment regimens for use as salvage therapy for DLBCL Extremely confident	Newer second-line treatment regimens for use as salvage therapy for DLBCL Very confident	Newer second-line treatment regimens for use as salvage therapy for DLBCL Moderately confident	Newer second-line treatment regimens for use as salvage therapy for DLBCL Slightly confident	Newer second-line treatment regimens for use as salvage therapy for DLBCL Not at all confident
Addition of autologous stem cell transplantation to supplement second-line therapy	Addition of autologous stem cell transplantation to supplement second-line therapy Extremely confident	Addition of autologous stem cell transplantation to supplement second-line therapy Very confident	Addition of autologous stem cell transplantation to supplement second-line therapy Moderately confident	Addition of autologous stem cell transplantation to supplement second-line therapy Slightly confident	Addition of autologous stem cell transplantation to supplement second-line therapy Not at all confident
Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL	Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL Extremely confident	Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL Very confident	Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL Moderately confident	Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL Slightly confident	Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL Not at all confident

Extremely confident

Very confident

Moderately confident

Slightly confident

Not at all confident

Selection of first-line therapy for GCB-DLBCL

Selection of first-line therapy for GCB-DLBCL Extremely confident

Selection of first-line therapy for GCB-DLBCL Very confident

Selection of first-line therapy for GCB-DLBCL Moderately confident

Selection of first-line therapy for GCB-DLBCL Slightly confident

Selection of first-line therapy for GCB-DLBCL Not at all confident

Selection of first-line therapy for ABC-DLBCL

Selection of first-line therapy for ABC-DLBCL Extremely confident

Selection of first-line therapy for ABC-DLBCL Very confident

Selection of first-line therapy for ABC-DLBCL Moderately confident

Selection of first-line therapy for ABC-DLBCL Slightly confident

Selection of first-line therapy for ABC-DLBCL Not at all confident

Selection of first-line therapy for primary mediastinal large B-cell lymphoma

Selection of first-line therapy for primary mediastinal large B-cell lymphoma Extremely confident

Selection of first-line therapy for primary mediastinal large B-cell lymphoma Very confident

Selection of first-line therapy for primary mediastinal large B-cell lymphoma Moderately confident

Selection of first-line therapy for primary mediastinal large B-cell lymphoma Slightly confident

Selection of first-line therapy for primary mediastinal large B-cell lymphoma Not at all confident

Newer second-line treatment regimens for use as salvage therapy for DLBCL

Newer second-line treatment regimens for use as salvage therapy for DLBCL Extremely confident

Newer second-line treatment regimens for use as salvage therapy for DLBCL Very confident

Newer second-line treatment regimens for use as salvage therapy for DLBCL Moderately confident

Newer second-line treatment regimens for use as salvage therapy for DLBCL Slightly confident

Newer second-line treatment regimens for use as salvage therapy for DLBCL Not at all confident

Addition of autologous stem cell transplantation to supplement second-line therapy

Addition of autologous stem cell transplantation to supplement second-line therapy Extremely confident

Addition of autologous stem cell transplantation to supplement second-line therapy Very confident

Addition of autologous stem cell transplantation to supplement second-line therapy Moderately confident

Addition of autologous stem cell transplantation to supplement second-line therapy Slightly confident

Addition of autologous stem cell transplantation to supplement second-line therapy Not at all confident

Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL

Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL Extremely confident

Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL Very confident

Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL Moderately confident

Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL Slightly confident

Consideration of allogeneic stem cell transplantation for relapsed/unresponsive DLBCL Not at all confident

Diffuse Large B-Cell Lymphoma Learner Survey

Question Title

* 1. What is your profession?

Question Title

* 2. What is your primary specialty?

Question Title

* 3. How aware are you of current recommendations by the NCCN regarding gene-expression profiling (GEP) classifications for the diagnosis of non-Hodgkin’s Lymphoma?

Question Title

* 4. How aware are you of imaging tools (ie, PET/CT scans) for staging diffuse large B-cell lymphoma (DLBCL)?

Question Title

* 5. How frequently do you use imaging tools (ie, PET/CT scans) to stage DLBCL?

Question Title

* 6. How aware are you of new molecular markers for classifying DLBCL patients into prognostic groups?

Question Title

* 7. If you are aware of these new molecular markers for classifying DLBCL, how often to you employ them to stage DLBCL?

Question Title

* 8. Which molecular markers do you use in diagnosing DLBCL sub-types?

Question Title

* 9. What factors determine your selection of first-line therapy in patients with germinal center B-cell like (GCB) DLBCL, which generally has a poorer response to standard rituximab-CHOP (R-CHOP) at greater risk of relapse?

Question Title

* 10. What other factors influence your selection of first-line therapy for DLBCL? (list all that apply)

Question Title

* 11. How aware are you of new investigational agents that may decrease the risk of DLBCL relapse (maintenance therapy)?

Question Title

* 12. What is your ideal maintenance therapy for patients with activated B-cell like (ABC) DLBCL?

Question Title

* 13. What is your ideal maintenance therapy for patients GCB-DLBCL?

Question Title

* 14. What do you believe is missing from the cadre of first-line agents and treatment regimens for the patients who fail to respond or relapse after initial therapy?

Question Title

* 15. How confident are you in the following tasks?

Question Title

* 16. How confident are you in each of the following?